BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 9532337)

  • 1. Treating severe Graves' ophthalmopathy.
    Bartalena L; Marcocci C; Pinchera A
    Baillieres Clin Endocrinol Metab; 1997 Oct; 11(3):521-36. PubMed ID: 9532337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Graves' ophthalmopathy: reality and perspectives.
    Bartalena L; Pinchera A; Marcocci C
    Endocr Rev; 2000 Apr; 21(2):168-99. PubMed ID: 10782363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism.
    Marcocci C; Bartalena L; Bogazzi F; Bruno-Bossio G; Pinchera A
    Thyroid; 1992; 2(2):171-8. PubMed ID: 1525588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of thyroid eye disease.
    Bartalena L; Marcocci C; Tanda L; Pinchera A
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S458-65. PubMed ID: 12192546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology and prevention of Graves' ophthalmopathy.
    Wiersinga WM; Bartalena L
    Thyroid; 2002 Oct; 12(10):855-60. PubMed ID: 12487767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graves' ophthalmopathy and 131I therapy.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Mazzi B; Rocchi R; Barbesino G; Pinchera A
    Q J Nucl Med; 1999 Dec; 43(4):307-12. PubMed ID: 10731781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on medical management of Graves' ophthalmopathy.
    Bartalena L; Marcocci C; Tanda ML; Piantanida E; Lai A; Marinò M; Pinchera A
    J Endocrinol Invest; 2005 May; 28(5):469-78. PubMed ID: 16075933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Graves' ophthalmopathy].
    Badelon I; Morax S
    Rev Prat; 2005 Jan; 55(2):183-6. PubMed ID: 15826000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid-associated Ophthalmopathy.
    Şahlı E; Gündüz K
    Turk J Ophthalmol; 2017 Apr; 47(2):94-105. PubMed ID: 28405484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Graves' ophthalmopathy by steroid therapy, orbital radiation therapy, plasmapheresis and thyroxine replacement.
    Yamamoto K; Saito K; Takai T; Yoshida S
    Endocrinol Jpn; 1982 Aug; 29(4):495-501. PubMed ID: 6897533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effects of intensive plasma exchange followed by immunosuppressive therapy in severe Graves' ophthalmopathy.
    Glinoer D; Etienne-Decerf J; Schrooyen M; Sand G; Hoyoux P; Mahieu P; Winand R
    Acta Endocrinol (Copenh); 1986 Jan; 111(1):30-8. PubMed ID: 2868602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orbital radiotherapy for Graves' ophthalmopathy.
    Bartalena L; Marcocci C; Tanda ML; Rocchi R; Mazzi B; Barbesino G; Pinchera A
    Thyroid; 2002 Mar; 12(3):245-50. PubMed ID: 11952048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study.
    Marcocci C; Bartalena L; Bogazzi F; Bruno-Bossio G; Lepri A; Pinchera A
    J Endocrinol Invest; 1991 Nov; 14(10):853-60. PubMed ID: 1802923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
    Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
    Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cigarette smoking and treatment outcomes in Graves ophthalmopathy.
    Bartalena L; Marcocci C; Tanda ML; Manetti L; Dell'Unto E; Bartolomei MP; Nardi M; Martino E; Pinchera A
    Ann Intern Med; 1998 Oct; 129(8):632-5. PubMed ID: 9786811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study.
    Marcocci C; Bruno-Bossio G; Manetti L; Tanda ML; Miccoli P; Iacconi P; Bartolomei MP; Nardi M; Pinchera A; Bartalena L
    Clin Endocrinol (Oxf); 1999 Oct; 51(4):503-8. PubMed ID: 10583319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of intensive plasma exchange followed by immunosuppressive therapy in severe Graves' ophthalmopathy.
    Glinoer D; Etienne-Decerf J; Schrooyen M; Sand G; Hoyoux P; Mahieu P; Winand R
    Metab Pediatr Syst Ophthalmol (1985); 1988; 11(3):133-40. PubMed ID: 3205168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endoscopic orbital decompression for Graves' ophthalmopathy.
    Levy J; Puterman M; Lifshitz T; Marcus M; Segal A; Monos T
    Isr Med Assoc J; 2004 Nov; 6(11):673-6. PubMed ID: 15562804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graves' ophthalmopathy: state of the art and perspectives.
    Bartalena L; Wiersinga WM; Pinchera A
    J Endocrinol Invest; 2004 Mar; 27(3):295-301. PubMed ID: 15165007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.